Addendum
Secukinumab - Addendum to Commission A15-20
Report documents
-
Addendum
Secukinumab - Addendum to Commission A15-20
Press releases
Secukinumab in psoriasis: now indication of added benefit for certain patients
Data subsequently submitted by the drug manufacturer provided better evidence for patients for whom other systemic treatments are not an option
Additional information
Federal Joint Committee (G-BA)
2015-11-27 A G-BA decision was published.
Project details
- Project no.
- A15-44
- Commission
- Commission awarded on 08.10.2015 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed